Affymax (Affymax) Cash And Cash Equivalents : $3.40 Mil (As of Jun. 2014)

View and export this data going back to 2006. Start your Free Trial

What is Affymax Cash And Cash Equivalents?

Affymax's quarterly cash and cash equivalents declined from Dec. 2013 ($5.60 Mil) to Mar. 2014 ($4.86 Mil) but then stayed the same from Mar. 2014 ($4.86 Mil) to Jun. 2014 ($3.40 Mil).

Affymax's annual cash and cash equivalents increased from Dec. 2011 ($54.34 Mil) to Dec. 2012 ($68.27 Mil) but then declined from Dec. 2012 ($68.27 Mil) to Dec. 2013 ($5.60 Mil).

Affymax Cash And Cash Equivalents Historical Data

The historical data trend for Affymax's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Cash And Cash Equivalents Chart

Affymax Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Cash And Cash Equivalents

Get a 7-Day Free Trial

125.30

63.50

54.34

68.27

5.60

Affymax Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Cash And Cash Equivalents	Get a 7-Day Free Trial															10.50	6.85	5.60	4.86	3.40

Affymax Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Affymax (OTCPK:AFFY) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Affymax Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Affymax's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax (Affymax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Executives

John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson	officer: Chief Financial Officer	8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp	officer: Chief Commercial Officer	4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte	director
Karin L Walker	officer: VP, Finance & CAO	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton	director
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland	officer: EVP, Corp. Development and CFO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris	director, officer: CEO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. Reports Operating Results (10-Q)

By gurufocus • 08-05-2009

AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares

By GuruFocus Research GuruFocus Editor • 02-26-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor • 05-19-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor • 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor • 05-13-2010

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares

By gurufocus • 09-03-2009